About Symbio
Symbio is a Healthcare company based in Port Jefferson (United States) founded in 2002, and was acquired by ARCHIMED in November 2023. Fertilizer commodities are traded and blended to meet client specifications. It operates on a Professional Services model. Symbio offers products and services including Clinical Research Services and Topical Formulation Development. Its focus areas include Clinical Research and Contract Research Organizations. Its competitors include Celgene, Syneos Health and Medelis WCCT Global; 2 of its 3 listed competitors have raised funding.
Company details
Symbio is established as a specialized Clinical Research Organization (CRO) with a focus on delivering full-service solutions for clinical trials across Phases I-IV and medical device trials. Expertise is provided in therapeutic areas such as Dermatology, Aesthetics, Inflammation, and Gastroenterology. Customized solutions are offered either as a full-service operation or as a Functional Service Provider (FSP). Services including project management, site feasibility, monitoring, medical writing, data management, and biostatistics are managed in-house. Global success is demonstrated through partnerships with sponsors and investigators, supported by offices in the USA and Europe. In collaboration with Dow Development Laboratories, LLC, turnkey solutions for drug formulation and development are also provided.
- Headquarters Port Jefferson, United States
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website symbioresearch.com
- Social LinkedIn
- Acquired by ARCHIMED (Nov 2023)
- Legal Name Symbio
Products & Services of Symbio
Symbio offers a comprehensive portfolio of products and services, including Clinical Research Services and Topical Formulation Development.
Clinical trials are managed across multiple therapeutic areas.
Drug formulations are developed for topical application purposes.
Investors in Symbio
Symbio has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include ARCHIMED.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare industries are funded and supported globally by ARCHIMED. | archimed.group | Lyon, France |
Investor details for Symbio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Symbio
11 people are tracked at Symbio (3 in leadership, 8 in team).
| Name | Role | Group |
|---|---|---|
Craig Wesselman | Director Of Statistics | Leadership |
Dr. Andreas Pfaff | Director Regulatory Affairs EU | Leadership |
Marie Tavani | Director Data Management | Leadership |
Chintan Arora | Statistical Programmer | Team |
Shrutimita Pokhariyal | Principal Statistician At Symbio Proinnovera | Team |
Saroja Kosaraju | Sr Statistical Programmer | Team |
Dawn Scharnhorst | Senior Analyst, Data Specifications | Team |
Levi Henson | Sr. Manager, EDC Development | Team |
Katelyn King | Clinical Project Manager I | Team |
Vedant Parashar | SAS Programmer I | Team |
Sadashiv Karankal | Sr. Biostatistician | Team |
Complete people profiles for Symbio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Symbio
2 dated milestones of Symbio across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Symbio is founded.
- Exit Acquired by ARCHIMED.
Competitors of Symbio
Symbio has 3 listed competitors in our database, 2 of them funded. They include Celgene, Syneos Health and Medelis WCCT Global.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| celgene.com | 1986 | Summit, United States | $45M | 4,891 | Therapies for cancer and inflammatory diseases are developed. | |
| syneoshealth.com | 1984 | Raleigh, United States | 29,395 | CRO clinical development services are provided by Syneos Health. | ||
| wcct.com | 1998 | Cypress, United States | $17M | 229 | Full-service CRO expertise in influenza and oncology research is offered. |
Detailed competitors of Symbio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Symbio
The website of Symbio (symbioresearch.com) receives about 3.5K visits a month.
- Monthly visits3.5K
▲ 59.5% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Symbio (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Symbio
Complete news archive for Symbio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Symbio
Symbio was founded in 2002.
Symbio is headquartered in Port Jefferson, United States. It is registered at Port Jefferson, New York, United States.
Symbio is established as a specialized Clinical Research Organization (CRO) with a focus on delivering full-service solutions for clinical trials across Phases I-IV and medical device trials. Expertise is provided in therapeutic areas such as Dermatology, Aesthetics, Inflammation, and Gastroenterology. Customized solutions are offered either as a full-service operation or as a Functional Service Provider (FSP). Services including project management, site feasibility, monitoring, medical writing, data management, and biostatistics are managed in-house. Global success is demonstrated through partnerships with sponsors and investigators, supported by offices in the USA and Europe. In collaboration with Dow Development Laboratories, LLC, turnkey solutions for drug formulation and development are also provided.
Symbio's top competitors include Syneos Health, Medelis WCCT Global and Celgene.
Symbio offers Clinical Research Services and Topical Formulation Development.
Symbio has 1 investor. Key investors include ARCHIMED.
Symbio operates through Symbio.
Yes. Symbio was acquired by ARCHIMED in November 2023.